ArticleBioresources and bioprocessing2026
Extracellular vesicles derived from the lactic acid bacterium Enterococcus rotai suppress melanogenesis by modulating the cAMP-MITF pathway.
Article in Bioresources and bioprocessing, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Enterococcus rotai CMTB-CA6-derived extracellular vesicles (CA6-ErEVs), isolated from a Centella asiatica-associated lactic acid bacterium, were investigated for their potential to modulate oxidative stress, inflammation, and melanogenesis in skin cells. CA6-ErEVs were purified and characterized using standardized nanoparticle analyses. Functional assays demonstrated that CA6-ErEVs displayed robust antioxidant activity by reducing free radical accumulation and intracellular reactive oxygen species levels. In tumor necrosis factor-α-stimulated dermal fibroblasts, CA6-ErEVs attenuated the secretion of proinflammatory cytokines and reduced matrix degradation while promoting procollagen synthesis. In α-melanocyte-stimulating hormone-activated murine and human melanocytes, CA6-ErEVs markedly suppressed melanin synthesis and tyrosinase activity, accompanied by the downregulation of microphthalmia-associated transcription factor (MITF) and key melanogenic enzymes including tyrosinase, tyrosinase-related protein 1, and tyrosinase-related protein 2. Mechanistically, CA6-ErEVs reduced intracellular cyclic adenosine monophosphate (cAMP) levels through intrinsic phosphodiesterase activity, thereby inhibiting the cAMP-MITF signaling axis and oxidative pathways involved in melanogenesis. Collectively, CA6-ErEVs exhibit integrated antioxidant, anti-inflammatory, and antimelanogenic effects through phosphodiesterase-mediated suppression of cAMP signaling and regulation of cellular redox balance. These findings highlight bacterial EVs derived from E. rotai as promising bioactive candidates for further development in the management of hyperpigmentation and improving cutaneous homeostasis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.